Uncategorized
Lampalizumab trial for geographic atrophy fails to meet endpoint
A phase 3 study of lampalizumab for geographic atrophy failed to meet its primary endpoint of reducing mean change in lesion area, Roche announced in a press release.The double-masked, randomized, global Spectri trial, the first of two phase 3 clinical trials, showed lampalizumab did not reduce mean change in geographic atrophy lesion area compared with sham treatment after 48 weeks.